$TMDX News

TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026

TransMedics Group (TMDX) Stock Looks Undervalued On Current Earnings

Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $94

Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

TransMedics Group (TMDX) Stock Looks Below Fair Value On Earnings

TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative Holds

TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?

TransMedics Offers An Attractive Entry Point, With Upside Potential Outweighing Risks

TransMedics: Waiting On 2027 Catalysts (Rating Upgrade)

TransMedics Group, Inc. (TMDX) Presents at 2026 Global Healthcare Conference - Slideshow

TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

TransMedics Group Appoints Fernando Araujo CFO, Effective Sept. 21; Reaffirms FY26 Revenue Range $737M - $757M

TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target

TransMedics: Slowing Growth Brings Its Valuation Into Question

TransMedics to Present at Upcoming September Investor Conferences

TransMedics Targets $2B Opportunity With Kidney Push, European Expansion

TransMedics (TMDX) Q2 2026 Earnings Call Transcript

TransMedics Group, Inc. (TMDX) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

TransMedics: Margins Down, Concentration Up, Trials Delayed